Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue

International Journal of Cancer

Volumn 65, Issue 2, 1996, Pages 214-220

  Zamora, Paul O ^a,b   Gulhke, Stefan ^a   Bender, Hans ^a   Diekmann, Daniella ^a   Rhodes, Buck A ^b   Biersack, Hans Jurgen ^a   Knapp Jr , F F ^c  

^a UNIVERSITY OF BONN   (Germany)

^b RhoMed Inc   (United States)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMININ PEPTIDE; MAG 3; OCTREOTIDE; SODIUM PERMEASE RE 188; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VAPREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIOISOTOPES; RECEPTORS, SOMATOSTATIN; RHENIUM; SOMATOSTATIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030046033     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19960117)65:2<214::aid-ijc15>3.0.co;2-d     Document Type: Article

References (20)

1. BANKS, W.A., KASTIN, A.J., RADULOVJC, S., CONLEY, F.K., JOHNSON, D.L. and SCHALLY, A.V., Selective uptake of the somatostatin analog RC-160 across the blood-brain barrier of mice with KHT sarcomas. Anti-Cancer Drugs, 3, 519-523 (1992).
2. 1]octreotide. Europ. J. nucl. Med., 21, 328-335 (1994).
3. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Europ. J. nucl. Med., 22, 608-616 (1995).
4. 188Re. In: M. Nicolini, B. Bandoli and U. Mazzi (eds.), Technetium chemistry and nuclear medicine, 4, pp. 367-372, SG Editoriali, Padua, Italy (1995)
5. HAYES, R.L., Chemistry and radiochemistry of metal-ion nuclides commonly employed in radiopharmaceuticals. In: N.D. Heindel, H.D. Burns, T. Honda and L.W. Brady (eds.), The chemistry of radiopharmaceuticals, pp. 155-168, Masson, NY (1978).
6. HOFLAND, L.J., VAN KOETSVELD, P.M., WAAIJERS, M., ZUYERWIJK, J. and LAMBERTS, S.W., Relative potencies of the somatostatin analogs octreotide, BIM-23014 and RC-160 on the inhibition of hormone-release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology, 134, 301-306 (1994).
7. KNAPP, F.F., JR., MIRZAHDEH, S., BEETS, A.L., SHARKEY, R., GRIFFITHS, G., JUWEID, M. and GOLDENBERG, D.M., Curie-scale tungsten-188/rhenium generators for routine clinical applications. In: M. Nicolini, G. Bandoli and U. Mazzi (eds.), Technetium and rhenium in chemistry and nuclear medicine, 4, pp. 319-324, SG Editoriali, Padua, Italy (1995).
8. 3]-octreotide; the Rotterdam experience with more than 1,000 patients. Europ. J. nucl Med., 20, 716-731 (1993).
9. KVOLS, L.K. and REUBI, J.C., The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J. biol. Med., 65, 505-518 (1992).
10. LAMBERTS, S.W., KRENNING, E.P. and REUBI, J.-C., The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocrin. Rev., 12, 450-482 (1991).
11. LOEVINGER, R., BUDINGER, T.F. and WATSON, E.E., MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York (1991).
12. PINSKI, J., HALMOS, G. and SCHALLY, A.V., Somatostatin analog RC-160 and bombesin/gastrin-related peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett., 71, 189-196 (1993a).
13. PINSKI, J., SCHALLY, A.V., HALMOS, G. and SZEPESHAZI, K., Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer, 55, 963-967 (1993b).
14. PRETLOW, T.G., DELMORO, C.M., DILLEY, G.G., SPADAFORA, C.G. and PRETLOW, T.P., Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res., 51, 3814-3817 (1991).
15. 131I-labeled antitenascin monoclonal antibody BC-2. Int. J. Cancer, 51, 7-13 (1992).
16. RIVA, P., ARISTA, A., TISON, V., STURIALE, C., FRANCESCHI, G., SPINELLI, A., RIVA, N., CASI, M., MOSCATELLI, G. and FRATTARELLI, M., Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer, 73 (Suppl. 3), 1076-1082 (1994).
17. SCHALLY, A.V., Oncological applications of somatostatin analogues. Cancer Res., 48, 6977-6985 (1988).
18. SIEGEL, J.A. and STABIN, M.G., Absorbed fractions for electrons and beta particles in spheres of various sizes. J. nucl. Med., 35, 152-156 (1994).
19. 1H-NMR and computer modeling conformational analysis. J. biol. Chem., 269, 12583-12588 (1994).
20. VERHELST, J., DELONGUEVILLE, M., ONGENA, P., DENIS, L. and MAHLER, C., Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta urol. belg., 62, 83-88 (1994).